Biotech Breakthrough Verdiva Raises $410M to Revolutionize Obesity Treatment with Game-Changing Weight Loss Drug
Verdiva, a biotechnology company, has burst onto the scene with a staggering $410 million Series A funding round. This monumental ...
Tag: Obesity
Biotech Blowup for BioAge’s Obesity Drug
BioAge's recent announcement that its phase 2 obesity study has been derailed by liver side effects has sent shockwaves through ...
Hidden Data on Obesity Drug Sends Amgen’s Market Value Plummeting by $12 Billion
In a stunning reversal of fortune, biotechnology giant Amgen Inc. suffered a staggering $12 billion loss in market capitalization after ...
Viking Therapeutics’ Oral Obesity Drug Shows Promising 6.8% Weight Loss, Boosting Stock as Phase 1 Data Rolls Out
In the competitive arena of oral obesity treatments, Viking Therapeutics has made a strong showing with its obesity medication VK2735, ...
Boehringer Ingelheim Ends Development of Obesity Drug in Gubra Partnership
In a recent announcement, Boehringer Ingelheim has decided to end the development of one of its obesity drug candidates from ...
